Mytide Therapeutics is committed to providing peptides to serve a diverse array of applications.
Business Model:
Revenue: $0
Employees: 1-10
Address: 451 D Street
City: Boston
State: MA
Zip: 02210
Country: US
Mytide is committed to providing peptides to serve a diverse array of applications. They intend to work closely with partners to overcome challenges in synthesizing and purifying particular classes of peptides of interest, identify useful peptide modifications, and design and construct peptide libraries. They provide initial partners access to their cloud platform for immediate ordering, properties calculator, order tracking, and interactive data display.
Contact Phone:
+12076594206
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2022 | Series A | $0 |
Alloy Therapeutics Trog Hawley Capital Uncommon Denominator Alloy Therapeutics Trog Hawley Capital Uncommon Denominator |
9/2019 | Grant | 2 | $200k |
Creative Destruction Lab (CDL) Massachusetts Life Sciences Center Creative Destruction Lab (CDL) Massachusetts Life Sciences Center |
1/2021 | Venture Round | - |
Uncommon Denominator Uncommon Denominator |
12/2021 | Series A | $7.1M |
Alloy Therapeutics Uncommon Denominator |
12/2022 | Series A | $1.2M | 12/2019 | Grant | 1 | $270k |
National Science Foundation National Science Foundation |
3/2022 | Series A | 3 | $7M |
Alloy Therapeutics Trog Hawley Capital Uncommon Denominator Alloy Therapeutics Trog Hawley Capital Uncommon Denominator |
1/2021 | Venture Round | 1 | - |
Uncommon Denominator Uncommon Denominator |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|